Rituximab (Rituxan®/MabThera®): The first decade (1993-2003)

Expert Review of Anticancer Therapy

Volumn 3, Issue 6, 2003, Pages 767-779

  Grillo López, Antonio J ^a  

^a Research Institute   (United States)

Author keywords

Apoptosis; Chimeric antibody; Immunotherapy; Lymphoma; MabThera; Monoclonal antibody; NHL; Rituxan; Rituximab

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BLEOMYCIN; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; INTERFERON; INTERLEUKIN 2; PREDNISONE; RICIN; RITUXIMAB; VINCRISTINE;

AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CANCER GRADING; CANCER PATIENT; CLINICAL TRIAL; DRUG ACTIVITY; DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PREDICTION; RADIOIMMUNOTHERAPY; REVIEW; STANDARDIZATION;

EID: 0346328325     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.6.767     Document Type: Review

References (77)

1. Multani P, White CA, Grillo-López AJ. Non-Hodgkin's lymphoma: review of conventional treatments. Curr. Pharm. Biotechnol. 2(4), 279-291 (2001).
2. Grillo-López AJ. Monoclonal antibodies in the treatment of hematologic malignancies. Curative therapies for NHL: a question of time! Curr. Pharm. Biotechnol. 2(4), 279-280 (2001).
3. Portlock CS, Rosenberg S. No initial therapy for Stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann. Intern. Med. 90, 10-13 (1979).
4. Horning S, Rosenberg S. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N. Engl. J. Med. 311, 1471-1475 (1984).
5. Grillo-Lopez AJ. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Rev. Anticancer Ther. 2(3), 323-329 (2002).
6. Peterson BA, Petroni GA, Frizzera G. Prolonged single agent versus combination chemotherapy in indolent follicular lymphomas. A study of the Cancer and Leukemia Group B. J. Clin. Oncol. 2, 5-15 (2003).
7. Horning SJ. Something old, something few, something subjective, something déjà vu. J. Clin. Oncol. 21, 1-2 (2003).
8. Coiffier B, Lepage E, Briére J et al. CHOP chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
9. Fisher R, Gaynor E, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328(14), 1002-1006 (1993).
10. Grillo-López AJ, White CA, Dallaire BK et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol. 1(1), 1-9 (2000).
11. Grillo-López AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev. Anticancer Ther. 2(5), 485-493 (2002).
12. Grillo-López AJ, Horning S, Cheson BD et al. Development of response criteria for low-grade or follicular lymphomas and application in a 166 patient study. Exp. Hematol. 25(8), 732 (1997).
13. Grillo-López AJ, Cheson BD, Horning SJ et al. Response criteria for NHL: importance of normal lymph node size and correlations with response rates. Ann. Oncol. 11, 399-408 (2000).
14. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J. Clin. Oncol. 17(4), 1244-1253 (1999).
15. Anderson DR, Grillo-López A, Varns C et al. Targeting cytotoxic immunotherapy: targeted anticancer therapy using rituximab, a chimeric antiCD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 25, 705-708 (1997).
16. Reff ME, Carner K, Chambers KS et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2), 435-445 (1994).
17. Schwaner I, Gerecke C, Srock et al. In vitro and in vivo complement activation by rituximab: differential in vivo effects. Blood 94(10 Suppl. 1), 90a (1999).
18. Pedersen IM, Jurlander J. The chimeric antiCD20 antibody Rituxan® can induce map-kinase phosphorylation, upregulation of proapoptotic proteins and apoptosis in B-cell chronic lymphocytic leukemia cells. Blood 94 (10 Suppl. 1), 120a (1999).
19. Demidem A, Lam T, Alas S et al. Chimeric antiCD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12(3), 177-185 (1997).
20. Sell S, Max E. Immunology, Immunopathology and Immunity (Sixth Edition). ASM Press, WA, USA (2001).
21. Berinstein NL, Grillo-López AJ, White CA et al. Association of serum rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9, 995-1001 (1998).
22. Czuczman MS, Grillo-López AJ, Maloney D et al. Rituximab clearance of bcl-2 from peripheral blood and bone marrow from patients with relapsed low-grade or follicular lymphoma. Proc. Am. Assoc. Cancer Res. 40, 719 (1999).
23. Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 10, 466-468 (2003).
24. Grillo-López AJ, Dallaire BK, McClure A et al. Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. Curr. Pharm. Biotechnol. 2, 301-311 (2001).
25. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric antiCD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84(8), 2457-2466 (1994).
26. Czuczman MS, Grillo-López AJ, McLaughlin P et al. Clearing of cells bearing the bcl-2 t(14,18) translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann. Oncol. 12, 109-114 (2001).
27. Bodkin D, Maloney D, Neidhart J et al. Pharmacokinetic analysis of serum concentrations of the chimeric antiCD20 antibody IDEC-C2B8 in patients with relapsed B-cell lymphoma. Proc. Am. Assoc. Cancer Res. 36, 365 (1995).
28. Horning S, Cheson B, Peterson B et al. Response criteria and quality assurance of responses in the evaluation of new therapies for patients with low-grade lymphoma. Proc. Am. Soc. Clin. Oncol. 16, 18a (1997).
29. Grillo-López AJ. Response evaluation in patients with low-grade or follicular NHL. Presentation to the Biological Response Modifiers Advisory Committee of the FDA, WA, USA (1996).
30. Grillo-López AJ. Response criteria and QA auditing of responses in low-grade or follicular lymphomas: experience in the IDEC-C2B8 single arm pivotal trial. Clinical Trials in Biotechnology Workshop, CA, USA (1997).
31. Grillo-López AJ, Cheson B, Horning S et al. Response criteria for NHL: importance of normal lymph node size and correlations with response. Blood 92(10), 412a (1998).
32. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J. Clin. Oncol. 17(4), 1244-1253 (1999).
33. Grillo-López AJ, McLaughlin P, Cheson B et al. First report on the application of the new response criteria proposed for NHL: the rituximab pivotal trial. Proc. Am. Soc. Clin, Oncol. 18, 13a (1999).
34. Grillo Lopez AJ, Varns C, Shen D et al. Standard and rigorously applied response criteria for NHL are essential for the interpretation of clinical trial results and comparison across studies reported in the literature. Ann. Oncol. 10(3), 178 (1999).
35. Grillo-López AJ, Cheson BD, Horning SJ et al. Response criteria for NHL: importance of normal lymph node size and correlations with response rates. Ann. Oncol. 11, 399-408 (2000).
36. Grillo-López AJ. Scientific and medical summary on IDEC-C2B8: Rituxan (rituximab). Biologics license application presentation to the Biological Response Modifiers Advisory Committee of the FDA, WA, USA (1997).
37. Saven A, Grillo-López AJ, Janakiraman N et al. Rituximab: pharmacokinetic/ pharmacodynamic correlations of extended dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma. Blood 96(11), 730a (2000).
38. Piro LD, White CA, Grillo-López AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10, 655-661 (1999).
39. Rosenberg S, Berard C, Brown J et al. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project. Cancer 49, 2112-2135 (1982).
40. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (rituximab) antiCD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6), 2188-2195 (1997).
41. McLaughlin P, Grillo-López AJ, Link BK et al. Chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program J. Clin. Oncol. 16, 2825-2833 (1998).
42. Davis TA, White CA, Grillo-López AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. J. Clin. Oncol. 17(6), 1851-1857 (1999).
43. Igarashi T, Ohtsu T, Fujii H et al. Retreatment of relapsed indolent B-cell lymphoma with rituximab. Int. J. Hematol. 73(2), 213-221 (2001).
44. Aviles A, Leon MI, Diaz-Maqueo JC et al. Rituximab in the treatment of refractory follicular lymphoma - six doses are better than four. J. Hematother. Stem Cell Res. 10(2), 313-316 (2001).
45. Feuring-Buske M, Kneba M, Unterhalt M et al. IDEC-C2B8 (rituximab) antiCD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a Phase-II study of the German Low-Grade Lymphoma Study Group. Ann. Hematol. 79(9), 493-500 (2000).
46. Foran JM, Gupta RK, Cunningham D et al. A UK multicentre Phase II study of rituximab (chimeric antiCD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109(1), 81-88 (2000).
47. Ghielmini M, Schmitz SF, Burki K et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann. Oncol. 11(Suppl. 1), S123-S126 (2000).
48. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade or follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20(10), 2453-2463 (2002).
49. Witzig TE, White CA, Gordon LI et al. Final results of a randomized controlled study of the Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL. Blood 96(11), 831a (2000).
50. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97(1), 101-106 (2001).
51. Grillo-López AJ, McLaughlin P, Czuczman M et al. Responders to rituximab show continued tumor regression over time and a progression-free survival that correlates with response classification. Blood 94(10 Suppl. 1), 89a (1999).
52. Czuczman MS, Grillo-López AJ, McLaughlin P et al. Clearing of cells bearing the bcl-2 t(14,18) translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann. Oncol. 12, 109-114 (2001).
53. Rogers J, Ward P, Jackson J et al. Analysis of bcl-2 t(14;18) translocation in relapsed B-cell lymphoma patients treated with the chimeric antiCD20 antibody IDEC-C2B8. Proc. Am. Assoc. Cancer Res. 37, 213 (1996).
54. Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter Phase II trial. Semin. Oncol. 29(1 Suppl. 2), 25-29 (2002).
55. Ghielmini M, Hsu Schmitz S-F, Cogliatti S et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomized SAKK trial. Blood 100, 161a (2002).
56. Davis TA, Grillo-López AJ, White CA et al. Rituximab antiCD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J. Clin. Oncol. 18(17), 3135-3143 (2000).
57. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood 92(6), 1927-1932 (1998).
58. Grillo-López AJ, White CA, Varns C et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. 26(5 Suppl. 14), 66-73 (1999).
59. Czuczman M, Grillo-López AJ, Saleh M et al. Phase II clinical trial of IDEC-C2B8/CHOP combination therapy in low-grade lymphoma: preliminary results. Proc. Am. Soc. Clin. Oncol. 14, 401 (1995).
60. Czuczman MS, Grillo-López AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric antiCD-20 monoclonal antibody and CHOP chemotherapy J. Clin. Oncol. 17(1), 268-276 (1999).
61. Czuczman MS, Grillo-López AJ, White CA et al. Progression-free survival after six years (median) follow-up of the first clinical trial of rituximab/CHOP chemoimmunotherapy. Blood 98(11), 601a (2001)
62. Vose JM, Link BK, Grossboard ML et al. Phase II Study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 19, 389-397, (2001).
63. Vose JM, Link BK, Grossbard ML et al. Long-term follow-up of a Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL). Blood 100(11), 361a (2002).
64. Coiffier B, Lepage E, Herbrecht R et al. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma. (DLCL): interim results of a randomized GELA trial. Blood 96(11), 223a (2000).
65. Coiffier B, Lepage E, Briére J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
66. Davis TA, Maloney DG, Grillo-López AJ et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a. Clin. Cancer Res. 6, 2644-2652 (2000).
67. Perrotta A, Abuel C. Response of chronic relapsing ITP of 10 years duration of rituximab. Blood 92(10 Suppl. 1), 88b (1998).
68. Saleh MN, Gutheil J, Moore M et al. A pilot study of anticancer MoAb rituximab in patients with refractory immune thrombocytopenic purpura. Blood 96(11), 252a (2000).
69. Saleh MN, Gutheil J, Moore M et al. A pilot study of the antiCD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin. Oncol. 27(6 Suppl. 12), 99-103 (2000).
70. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 52, 1701-1704 (1999).
71. Lee E, Zamkoff KW, Gentile TC et al. Rituxan in the treatment of autoimmune hemolytic anemia (AIHA). Blood 96(11), 596a-597a (1999).
72. Karwal MW, Schlueter AJ, Zenk DW et al. Treatment of acquired Factor VIII deficiency with rituximab. Blood 96(11), 84b (2000).
73. Gajra A, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with lymphoma: first report. Blood 96(11), 237b (2000).
74. Protheroe A, Edwards JC, Simmons A et al. Remission of inflammatory arthropathy in association with antiCD20 therapy for non-Hodgkin's lymphoma. Rheumatology 38(11), 1150-1152 (1999).
75. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B-lymphocytes. Rheumatology 40, 205-211 (2001).
76. Grillo-Lopez AJ. Rituximab: clinical development of the first therapeutic antibody for cancer. In: Applications of Pharmaceutical Biotechnology: a Comprehensive Textbook, Kayser O, Müller R (Eds), Wiley-VCH, Weinheim, Germany (2003) (In Press).
77. Shipp MA, Ambinder RF, Zelenetz AD. NCCN Preliminary Non-Hodgkin's, Lymphoma Practice Guidelines. Oncology 11(11A), 281-346 (1997).